Elana Bernstein is a Rheumatology/Immunology physician affiliated with Columbia University Irving Medical Center. OpenAlex indexes 144 publications with 8,024 citations (h-index 29).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
535 E 70th St
New York, NY 100214823
Telephone
212-774-2788Registry record last updated 17 Oct 2013.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20252 payments
- Boehringer Ingelheim International GmbHProgram year20252 payments
- Boehringer Ingelheim International GmbHProgram year202422 payments$34,176openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
32.3%Interleukin-6 Receptor Antagonist17.9%Actemra69%Actemra Actpen31%Part D<11 patientsFolate Analog Metabolic Inhibitor9%Methotrexate100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
30.3%Proton pump inhibitor19.4%Omeprazole100%Part D≥11 patientsCorticosteroid10.9%Prednisone100%Part D<11 patientsMusculoskeletal
10.4%Nonsteroidal Anti-inflammatory Drug10.4%Diclofenac Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2019–2026 per NIH RePORTER. The latest:
- Vasculopathy and Systemic Sclerosis-Associated Interstitial Lung Disease
Columbia University Health Sciences
FY2026$626,903R01HL164758 - Vasculopathy and Systemic Sclerosis-Associated Interstitial Lung Disease
Columbia University Health Sciences
FY2025$704,693R01HL164758 - Vasculopathy and Systemic Sclerosis-Associated Interstitial Lung Disease
Columbia University Health Sciences
FY2024$699,456R01HL164758
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Rebecca Hahn, MD
Columbia University Irving Medical Center
Susheel Kodali, MD
Columbia University Irving Medical Center
Ronald Wapner, MD
Columbia University Irving Medical Center
Lawrence Honig, MD
Columbia University Irving Medical Center
David Felson, MD
Boston University
Marc Hochberg, MD
University of Maryland School of Medicine
Philip Mease, MD
Michelle Petri, MD
Johns Hopkins University School of Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”